Sellas Receives European Medicines Agency Orphan Drug Designation for Sls009 for the Treatment of Acute Myeloid Leukemia
Sellas公司因Sls009用於治療急性髓細胞白血病而獲得歐洲藥品管理局孤兒藥品認定。
Sellas Receives European Medicines Agency Orphan Drug Designation for Sls009 for the Treatment of Acute Myeloid Leukemia
Sellas公司因Sls009用於治療急性髓細胞白血病而獲得歐洲藥品管理局孤兒藥品認定。
譯文內容由第三人軟體翻譯。